STERIS plc $STE Shares Acquired by Gotham Asset Management LLC

Gotham Asset Management LLC lifted its holdings in shares of STERIS plc (NYSE:STE) by 26.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 163,857 shares of the medical equipment provider’s stock after purchasing an additional 34,003 shares during the period. Gotham Asset Management LLC owned about 0.17% of STERIS worth $40,545,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Steigerwald Gordon & Koch Inc. acquired a new stake in STERIS during the 3rd quarter valued at $25,000. Cloud Capital Management LLC acquired a new position in shares of STERIS in the third quarter worth $29,000. Geneos Wealth Management Inc. lifted its position in shares of STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares in the last quarter. TruNorth Capital Management LLC purchased a new stake in shares of STERIS in the third quarter valued at $37,000. Finally, Root Financial Partners LLC acquired a new stake in shares of STERIS during the third quarter valued at $39,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Trading Up 1.1%

Shares of STE opened at $214.66 on Monday. STERIS plc has a fifty-two week low of $204.90 and a fifty-two week high of $269.44. The company has a market capitalization of $21.05 billion, a PE ratio of 29.94 and a beta of 1.05. The stock has a fifty day moving average of $250.96 and a two-hundred day moving average of $250.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The firm’s revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, analysts forecast that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, February 17th. STERIS’s dividend payout ratio (DPR) is presently 35.15%.

Insider Buying and Selling

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of STERIS stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $237.21, for a total value of $734,876.58. Following the completion of the sale, the director owned 705 shares in the company, valued at $167,233.05. The trade was a 81.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.07% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on STE shares. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.20.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.